Tvardi Therapeutics Reports Phase 2 Data Showing TTI-101 Reduces Fibrosis in IPF Patients
I'm PortAI, I can summarize articles.
Tvardi Therapeutics Inc. has reported updates from its Phase 2 REVERT IPF clinical trial for TTI-101, an oral STAT3 inhibitor, in idiopathic pulmonary fibrosis (IPF) patients. Despite not meeting primary endpoints in October 2025, data from 40 patients show a 9.4% reduction in fibrosis score with TTI-101 compared to 2.4% in the placebo group. Additionally, 63% of TTI-101 patients had increased forced vital capacity (FVC) at 12 weeks, versus 46% in the placebo group. The company anticipates topline data from a Phase 1 study of TTI-109 in early 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments